Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.

ABSTRACT: Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the most difficult cancers to treat in both the primary and recurrent settings. GBM presents a unique therapeutic challenge given the immune-privileged environment of the brain and the aggressive nature of the disease. Furthermore, it can change phenotypes throughout the course of disease-switching between mesenchymal, neural, and classic gene signatures, each with specific markers and mechanisms of resistance. Recent advancements in the field of immunotherapy-which utilizes strategies to reenergize or alter the immune system to target cancer-have shown striking results in patients with many types of malignancy. Immune checkpoint inhibitors, adoptive cellular therapy, cellular and peptide vaccines, and other

SUBMITTER: Kreatsoulas D 

PROVIDER: S-EPMC9188021 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature